Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Lupin Introduces Lurasidone Hydrochloride Tablets in the U.S
Lurasidone is prescribed to adults and children 13 years of age and older to treat the symptoms of schizophrenia.
Mumbai: Lupin, an innovation-led transnational pharmaceutical company has launched Hydrochloride Tablets as a generic equivalent to Sunovion Pharmaceuticals, Inc.'s Latuda Tablets used for treating depressive episodes associated with bipolar disorder.
Lurasidone, available in dosages of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, is used to treat the symptoms of schizophrenia (a mental illness characterised by disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and children 13 years of age and older.
According to IQVIA MAT December 2022, annual sales of Lurasidone Hydrochloride Tablets (RLD Latuda) in the United States were estimated to be USD 4.2 billion.
According to a company statement shared with stock exchanges on Tuesday, the company develops and commercialises a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.